RxDoctor Payments Data

Gregory Stewart

Optometrist · Athens, ALNPI 1073964193

Payments from drug & device makers

$2,348in general payments, 2019–2025

Across 81 payments — averaging $28.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$427
  • Johnson & Johnson Vision Care, Inc.$308
  • Alcon$307
  • Bausch & Lomb Americas Inc.$276
  • Oyster Point Pharma, Inc.$188
  • Biotissue Holdings Inc.$162
  • plus $679 from 10 others

What the payments were for

  • Food & beverage$2,348100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,348 in reported general payments places this provider in the 70th percentile of 749 optometrist providers in Alabama.

See all optometrist providers in Alabama

Medicare billing

Part B allowed, 2024
$60,871
Medicare patients
329
Services billed
726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine29$26,971
MieboPerfluorohexyloctane/Pf20$14,889
CombiganBrimonidine Tartrate/Timolol24$10,827
LumiganBimatoprost21$10,161
RocklatanNetarsudil Mesylat/Latanoprost13$4,073
Travoprost31$3,265
ZioptanTafluprost/Pf12$3,042
Latanoprost217$2,567
Dorzolamide-TimololDorzolamide/Timolol/Pf20$2,300
Prednisolone Acetate21$806
Timolol Maleate95$615
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat26$573
Tobramycin-DexamethasoneTobramycin/Dexamethasone11$516
Dorzolamide Hcl24$509
Brimonidine Tartrate55$400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$427$47,95874 claims
Bausch & Lomb Americas Inc.Miebo$276$14,88920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 749 optometrist providers in Alabama.

Other optometrist in Athens

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →